Octreotide
1
Reactions 1455 - 8 Jun 2013 S Octreotide Multifocal central nervous system demyelination: case report A 52-year-old woman developed multifocal central nervous system (CNS) demyelination after octreotide treatment for metastatic meningioma. In preparation for planned salvage therapy for metastatic meningioma, the woman received low-dose SC octreotide 0.1mg three times daily. On treatment day 21 new intermittent bilateral paraesthesia developed in the L3–L5 dermatomes. The woman was admitted, and octreotide was withdrawn on day 25. An MRI on day 28 showed three new periventricular/ subcortical and two spinal T2-hyperintense lesions without contrast enhancement or diffusion restriction. Analysis of CSF during the acute phase and at 6 months’ follow-up was consistent with chronic CNS inflammation. Subsequent to stopping octreotide, she did not report any additional neurological symptoms, but continued to experienced paraesthesia after exposure to heat (e.g. in a sauna). Author comment: "We report the development of probably autoimmune-mediated multifocal demyelination after octreotide treatment in a patient with meningioma. The onset of clinical symptoms during treatment as well as MRI and CSF changes are suggestive of an immune process triggered by octreotide administration". Schreglmann SR, et al. Multifocal CNS demyelination after octreotide treatment for metastatic meningioma. Clinical Neurology and Neurosurgery 115: 817-819, No. 6, Jun 2013. Available from: URL: http://dx.doi.org/10.1016/ j.clineuro.2012.07.021 - Switzerland 803087973 1 Reactions 8 Jun 2013 No. 1455 0114-9954/10/1455-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Octreotide
Reactions 1455 - 8 Jun 2013
SOctreotide
Multifocal central nervous system demyelination:case report
A 52-year-old woman developed multifocal central nervoussystem (CNS) demyelination after octreotide treatment formetastatic meningioma.
In preparation for planned salvage therapy for metastaticmeningioma, the woman received low-dose SC octreotide0.1mg three times daily. On treatment day 21 new intermittentbilateral paraesthesia developed in the L3–L5 dermatomes.
The woman was admitted, and octreotide was withdrawn onday 25. An MRI on day 28 showed three new periventricular/subcortical and two spinal T2-hyperintense lesions withoutcontrast enhancement or diffusion restriction. Analysis of CSFduring the acute phase and at 6 months’ follow-up wasconsistent with chronic CNS inflammation. Subsequent tostopping octreotide, she did not report any additionalneurological symptoms, but continued to experiencedparaesthesia after exposure to heat (e.g. in a sauna).
Author comment: "We report the development ofprobably autoimmune-mediated multifocal demyelinationafter octreotide treatment in a patient with meningioma. Theonset of clinical symptoms during treatment as well as MRIand CSF changes are suggestive of an immune processtriggered by octreotide administration".Schreglmann SR, et al. Multifocal CNS demyelination after octreotide treatmentfor metastatic meningioma. Clinical Neurology and Neurosurgery 115: 817-819,No. 6, Jun 2013. Available from: URL: http://dx.doi.org/10.1016/j.clineuro.2012.07.021 - Switzerland 803087973
1
Reactions 8 Jun 2013 No. 14550114-9954/10/1455-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
![BS 499 Part 1 [1965]](https://static.fdocuments.nl/doc/165x107/54081862dab5cac8598b460a/bs-499-part-1-1965.jpg)
